Company Update (NYSE:ABBV): AbbVie to Present Data from Studies of DUOPA® (carbidopa and levodopa) Enteral Suspension in Advanced Parkinson’s Disease During the International Congress of Parkinson’s Disease and Movement Disorders
June 12, 2015 at 09:00 AM EDT
[PR Newswire] – NORTH CHICAGO, Ill., June 12, 2015 /PRNewswire/ — AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced it will present data from studies of DUOPA® (carbidopa and levodopa) enteral … . . . → Read More: Company Update (NYSE:ABBV): AbbVie to Present Data from Studies of DUOPA® (carbidopa and levodopa) Enteral Suspension in Advanced Parkinson’s Disease During the International Congress of Parkinson’s Disease and Movement Disorders Similar Articles: Stock Update (NYSE:ABBV): AbbVie to Present at UBS Global Healthcare Conference Stock Update: AbbVie Inc (NYSE:ABBV) – AbbVie to Present at Barclays Global Health Care Conference Market Update: AbbVie Inc (NYSE:ABBV) – AbbVie Announces U.S. FDA Approval of DUOPA™ (carbidopa and levodopa) Enteral Suspension for the Treatment of Motor Fluctuations in Patients with Advanced Parkinson’s Disease